Comparison 1. Fondaparinux versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pulmonary embolism	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2 Deep vein thrombosis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3 Deep vein thrombosis or pulmonary embolism	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Extension of superficial thrombophlebitis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5 Recurrence of superficial thrombophlebitis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6 Mortality	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7 Major bleeding	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
8 Clinically relevant non‐major bleeding	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9 Minor bleeding	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
10 Arterial thromboembolic complication	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
11 Adverse effects of treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
12 Non‐fatal serious adverse event	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected